Multiple NIH, investigator or industry-sponsored sample collections are housed in the ACI Biorepository. Access to information or requires submission of the appropriate Materials/Data Request Form. Upon receipt, the project plans will be reviewed and availability/suitability of the samples for the intended projects will be assessed. The requesting investigator will be contacted for any clarification of the request, or to provide expert guidance on sample suitability/availability or restrictions. Once approved (either through Advisory Committee guidance, or direct approval by the Advisory Committee, a sample cost-recovery estimate (if required) and confirmation of IRB/suitable MTA documentation will be performed.
Collections include Rheumatic Disease Collections, Other Autoimmune Disease Collections, Clinical Trial Collections. (Note: each collection is governed by its own advisory committee and collection owner/responsible party. Access will be determined on a case-by-case basis according to the particular repository restrictions on use, intended use, and consents provided.
Rheumatic Disease Collections:
- Oklahoma Rheumatic Disease Cohort (OMRF)
- Oklahoma Influenza Vaccination Response Cohort (OMRF-James)
- Lupus Family Registry and Repository (OMRF – NIAMS supported)
- Oklahoma Pediatric Lupus Registry and Repository (OMRF)
- Oklahoma SLE Case-Control Genetic Collections (OMRF)
- Oklahoma Immune Cohort (OMRF – James, NIGMS supported)
- Clinical Immunology Serum Repository (OMRF – James)
Other Autoimmune/Other Disease Collections:
- Oklahoma Multiple Sclerosis Cohort (OMRF – G. Pardo)
- Oklahoma Diabetes Cohort (Harold Hamm Diabetes COBRE – J. Ma, OUHSC)
- SOONER Osteoarthritis Cohort (OUHSC – M. Jeffries)
Clinical Trial Collections:
- Autoimmunity Centers of Excellence Trials (NIAID supported)
- A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, for the Treatment of Primary Sjögren’s Syndrome (ASJ02)
- An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE) (ALE06)
- Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA) (ARA08)
- NIAMS Prevention Trial
- Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)
- Accelerating Medicines Partnership in RA/SLE (NIAMS, NIAID, Industry sponsors)
Investigator Initiated/Industry Sponsored Clinical Trials
- Pfizer: Biomarkers of Lupus Disease: Study of Biomarker Changes Before and After Treatment With Depomedrol and Background Medication Withdrawal in Patients With Mild to Moderate SLE Disease Activity (BOLD)
- Bristol-Myers Squibb: Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches (The ABC Study)
- GlaxoSmithKline: Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy (BLAST)
- Bristol-Myers Squibb: MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE (MEASURE)